Australia-wide dispatch

Quantified
Peptides
ARA 290 16mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

ARA 290

Araim Pharmaceuticals 290, non-haematopoietic EPO derivative. Supplied as a lyophilised powder in 16mg vials.

Supplied as lyophilised powder in a 16mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About ARA 290

Araim Pharmaceuticals 290

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

ARA 290 is a synthetic 11-amino acid peptide derived from the helix B surface of erythropoietin (EPO). Unlike full EPO, it is engineered to selectively activate the Innate Repair Receptor (IRR), a heterodimeric receptor composed of the EPO receptor and the common beta chain (CD131), without stimulating erythropoiesis.

Research has explored ARA 290's tissue-protective and anti-inflammatory properties across multiple models, including neuropathy, metabolic disease, and inflammatory conditions. Clinical studies in sarcoidosis-associated small fibre neuropathy have examined its effects on corneal nerve fibre density and pain metrics, representing one of the more advanced clinical applications of IRR-targeted peptide research.

Origin
Non-haematopoietic EPO derivative
Research Areas
Neuroprotection, anti-inflammatory, small fibre neuropathy
Amino Acids
11 residues
Target
Innate Repair Receptor (IRR)
Haematopoietic Effect
None — non-erythropoietic
Clinical Research
Small fibre neuropathy, sarcoidosis
Key Pathway
EPO-R / CD131 (IRR) signalling
Research Status
Phase 2 clinical trials
  1. 01Innate Repair ReceptorARA 290 is designed to selectively activate the Innate Repair Receptor (IRR), a heterodimer of EPO receptor and CD131. Research examines tissue protective effects without the haematopoietic side effects of full erythropoietin.
  2. 02NeuroprotectionLaboratory and clinical research has investigated ARA 290's role in small fibre neuropathy, with studies examining nerve fibre regeneration and pain modulation pathways in diabetic and inflammatory neuropathy models.
  3. 03Anti-InflammatoryResearch has examined ARA 290's effects on macrophage polarisation and pro-inflammatory cytokine expression, proposing roles in resolving chronic inflammatory states in tissue protection research models.

References

  1. 1Brines M et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. PNAS. 2004;101(41):14907-14912.
  2. 2Niesters M et al. ARA 290 in sarcoidosis with small fibre neuropathy. Mol Med. 2013;19:256-261.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=ARA+290+peptide
  4. 4Heij L et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fibre loss. Mol Med. 2012;18(1):1272-1279.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range
KPV 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

KPV

$60